Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and Meta-analysis

被引:0
作者
Xin, Luo [1 ,2 ]
Jing, Xie [1 ,2 ]
Li, Huang [1 ,2 ]
Wenfan, Gan [1 ,2 ]
Ming, Chen [1 ,2 ]
机构
[1] Univ Tradit Chinese Med, Hosp Chengdu, Chengdu 610072, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu 610075, Peoples R China
基金
中国国家自然科学基金;
关键词
Medicine; Chinese traditional; activating blood circulation and removing blood stasis; renal fibrosis; efficacy; safety; Meta-analysis; systematic review; GROWTH-FACTOR-BETA; TUBULOINTERSTITIAL FIBROSIS; PATHOGENESIS; MECHANISMS; NEPHROPATHY; EXPRESSION; PRESSURE; ORIGIN; CELLS;
D O I
10.19852/j.cnki.jtcm.20230308.003
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To evaluate the efficacy and safety of activating blood circulation and removing blood stasis in terms of Traditional Chinese Medicine (TCM) for managing renal fibrosis (RF) in patients with chronic kidney disease (CKD). METHODS: We searched randomized controlled trials (RCTs) from eight databases. RESULTS: Sixteen eligible studies with 1,356 participants were included in this study. Compared to treatment with Western Medicine (WM) alone, the combined treatment with activating blood circulation and removing blood stasis in terms of TCM (ARTCM) and WM to manage RF in patients with CKD significantly ameliorated type IV collagen (C -IV) (SMD:-2.17, 95% CI: 3.01 to-1.34), type III procollagen (PC -III) (SMD: -1.08, 95% CI:-1.64 to-0.53), laminin (LN) (SMD: -1.28, 95% CI:-1.65 to-0.90), transforming growth factor beta 1 (TGF-beta 1) (SMD:-0.65, 95% CI:-1.18 to -0.12), serum creatinine (Scr) (SMD:-1.36, 95% CI: -1.85 to-0.87), blood urea nitrogen (BUN) (MD:-1.51, 95% CI:-2.59 to-0.43), and 24 h urine protein (24hUpro) (SMD:-1.23; 95% CI:-1.96 to-0.50). The level of hyaluronic acid (HA) was similar in both types of treatment (SMD:-0.74, 95% CI:-1.91 to 0.44). The subgroup analysis showed that the duration of 8 weeks might affect the concentration of C-IV, PC-III, and LN (P < 0.05). The effectiveness of the longer duration to C -IV, PC-III, and LN was not certain. However, the result should be interpreted in care. The safety of the treatment using ARTCM and WM could not be evaluated because a few studies had reported adverse effects. The results of the Meta -analysis were not stable enough. There was publication bias for the reports on Scr (P = 0.001), C-IV (P = 0.001), PC-III (P = 0.026), and LN (P = 0.030) and no publication bias for the reports on BUN (P = 0.293). The quality of evidence varied from low to very low. CONCLUSIONS: The combined treatment using ARTCM and WM to manage RF in patients with CKD has some advantages over treatment with WM alone. High -quality RCTs need to be conducted for the strong support.
引用
收藏
页码:429 / 440
页数:12
相关论文
共 80 条
[1]  
Abdualkader AM, 2013, INDIAN J PHARM SCI, V75, P127
[2]   ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 [J].
Amann, B ;
Tinzmann, R ;
Angelkort, B .
DIABETES CARE, 2003, 26 (08) :2421-2425
[3]  
[Anonymous], 2008, DAN XI XIN FA, P160
[4]   Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].
Bikbov, Boris ;
Purcell, Carrie ;
Levey, Andrew S. ;
Smith, Mari ;
Abdoli, Amir ;
Abebe, Molla ;
Adebayo, Oladimeji M. ;
Afarideh, Mohsen ;
Agarwal, Sanjay Kumar ;
Agudelo-Botero, Marcela ;
Ahmadian, Elham ;
Al-Aly, Ziyad ;
Alipour, Vahid ;
Almasi-Hashiani, Amir ;
Al-Raddadi, Rajaa M. ;
Alvis-Guzman, Nelson ;
Amini, Saeed ;
Andrei, Tudorel ;
Andrei, Catalina Liliana ;
Andualem, Zewudu ;
Anjomshoa, Mina ;
Arabloo, Jalal ;
Ashagre, Alebachew Fasil ;
Asmelash, Daniel ;
Ataro, Zerihun ;
Atout, Maha Moh'd Wahbi ;
Ayanore, Martin Amogre ;
Badawi, Alaa ;
Bakhtiari, Ahad ;
Ballew, Shoshana H. ;
Balouchi, Abbas ;
Banach, Maciej ;
Barquera, Simon ;
Basu, Sanjay ;
Bayih, Mulat Tirfie ;
Bedi, Neeraj ;
Bello, Aminu K. ;
Bensenor, Isabela M. ;
Bijani, Ali ;
Boloor, Archith ;
Borzi, Antonio M. ;
Camera, Luis Alberto ;
Carrero, Juan J. ;
Carvalho, Felix ;
Castro, Franz ;
Catala-Lopez, Ferran ;
Chang, Alex R. ;
Chin, Ken Lee ;
Chung, Sheng-Chia ;
Cirillo, Massimo .
LANCET, 2020, 395 (10225) :709-733
[5]   Renal fibrosis: novel insights into mechanisms and therapeutic targets [J].
Boor, Peter ;
Ostendorf, Tammo ;
Floege, Juergen .
NATURE REVIEWS NEPHROLOGY, 2010, 6 (11) :643-656
[6]  
BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104
[7]   Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold [J].
Buelow, Roman David ;
Boor, Peter .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2019, 67 (09) :643-661
[8]   Effects of tanshinone IIA on the regulation of renal proximal tubular fibrosis [J].
Cao, Luoyuan ;
Huang, Baoying ;
Fu, Xianguo ;
Yang, Jing ;
Lin, Yinghua ;
Lin, Feng .
MOLECULAR MEDICINE REPORTS, 2017, 15 (06) :4247-4252
[9]   Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia [J].
Chade, AR ;
Mushin, OP ;
Zhu, XY ;
Rodriguez-Porcel, M ;
Grande, JP ;
Textor, SC ;
Lerman, A ;
Lerman, LO .
HYPERTENSION, 2005, 46 (04) :772-779
[10]  
Chen BM, 2020, ZHONG GUO ZHONG YI Y, V18, P53